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Infotech and biotech: learning the lessons
Richard G.A. Feachem1
The development of the World Wide
Web has arguably had a profound
influence on many facets of life in almost
every country over the past decade. The
pace of innovation, in both hardware and
software, has not slackened and equally
momentous changes can be anticipated
in the coming decade. The manner in
which this has been achieved is remark-
able. Governments, especially that of
the USA, invested in basic research in
both public laboratories and at public and
private universities. Private companies,
both small and large, took the fruits
of this research and translated them into
products. These products diffused
rapidly around the globe and within just
a few years became of benefit to people
of all countries, and not only to the
rich and powerful in a few.
Aspects of this process are note-
worthy. First, there has been no World
Information Technology Organization
to guide and direct the development
and diffusion of information technology
(IT) — thank goodness! Second, there
has been minimal governmental regula-
tion and interference in the commercia-
lization of IT. Third, unlike the steam
engine, electricity, and the telephone,
the new IT has spread throughout the
world with extreme rapidity and is
theoretically available to those who are
literate almost everywhere. Fourth, one
developing country, India, has played
a leading role in furthering these tech-
nologies and in their commercialization.
This can be seen both in the prominence
of Indian engineers and business people
in Silicon Valley in California, USA, and
in the home-grown IT industry that
is now so buoyant in Bangalore,
Hyderabad, and elsewhere in India.
Biotechnology, like IT, is growing
rapidly and brings with it the promise
of important new tools for the treatment
and prevention of disease. The benefi-
ciaries of this biotechnology revolution
are largely citizens of wealthy countries
and, to some extent, the middle classes
in middle-income and large low-income
countries. The poor are not benefiting
and, with current arrangements and
incentives, will not benefit. The digital
divide may not be such a concern,
but the biotechnology divide certainly is.
To try to fix this problem and to
bring the fruits of biotechnology to
all who can benefit from them, public–
private partnerships (PPPs) have become
a popular model. The theme section of
this issue of the Bulletin focuses on PPPs
for drugs and vaccines and on incentives
for private-sector engagement in diseases
of the poor. I am an acknowledged fan
of these new PPPs and am closely
associated with their most successful
example — namely the International
AIDS Vaccine Initiative (IAVI). How-
ever, I see some limitations in the current
arrangements and some lessons to be
drawn from the IT experience.
First, it would be a mistake to try to
over-manage the process. Progress will
not come from carefully orchestrated and
coordinated central planning by an inter-
national agency. Progress will come from
diversity, from risk taking, and from
numerous points of energy and initiative.
To paraphrase Mao Tse-tung ‘‘Let a
hundred technologies bloom; let a
hundred initiatives contend’’. Second,
we must accept failure. Some PPPs will
achieve little and should be terminated;
some brave private ventures will go
bankrupt. We should regard a certain
amount of failure as a sign that we are
probably doing the right thing and are
on the right track.
Third, but most importantly, we
must pay attention to the incentives. For
the private sector to engage seriously in
the development and marketing of drugs
and vaccines for neglected diseases of the
poor, the incentivesmust be aligned. This
requires government action in rich and
poor countries to create both ‘‘push’’
and ‘‘pull’’ mechanisms (see Webber &
Kremer, pp. 735–741). It also requires
the gradual development of a self-
sustaining market. There is no funda-
mental reason why the diseases of two-
thirds of the world’s population should
be of such little commercial interest to
the pharmaceutical and biotechnology
industry. If individuals and governments
purchased rationally, the market would
be large, characterized by high volumes
and low margins. Admittedly, govern-
ments of very poor countries simply
cannot afford to purchase rationally on
behalf of their populations and so in these
cases, large and sustained international
assistance is required. Such assistance is
becoming increasingly available through
the actions of the Global Alliance on
Vaccines and Immunization (GAVI)
and the new Global Fund.
The last lesson from IT is to watch
out for the rise of biotechnology and
research-based pharmaceutical industries
in a few key developing countries. This
rise will be rapid, partly because circum-
stances are now favourable and partly
because of compliance with TRIPS
(trade-related aspects of intellectual
property rights). It is plausible that by
2010, the centre of gravity of innovation
in drugs and vaccines will have moved
noticeably towards developing countries.
This can only bring benefit to the world,
although as Kettler & Modi point out
(pp. 742–747), it is not a foregone
conclusion that industries in poor coun-
tries will focus on diseases of the poor.
New incentive mechanisms will be as
necessary for them as they are for
companies in rich countries.
It is clearly a priority to apply fully
and effectively existing technology to
control and treat themajor diseases of the
developing world. We are far from doing
this at the present time. It is equally a
priority to harness the biomedical and
biotechnology revolution to develop new
drugs and vaccines. Today we lack
adequate drugs and vaccines for tuber-
culosis, malaria, and HIV/AIDS: three
of the globe’s biggest killers. To develop
these new technologies and products
will require action by governments and
the private sector; either alone will be
insufficient. Governments’ role should
be in investing in basic research and
creating an incentive environment which
will attract private investment. There are
encouraging signs of this type of action in
both Europe and the USA. Muchmore is
needed, however, and it is needed
urgently. n
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